Testimonials

Rebound tonometry is a great alternative to the Goldmann applanation tonometer in both screening and follow-up of glaucoma patients. It is a very reliable technology with a wide range of clinical applications and its use has become widespread in our practices.

As early adopters of Icare technology, we have many years of experience with the devices. The ic100 has been a wonderful advancement.  The added features that assist the operator with proper alignment ensures the measurements are repeatable and accurate. It is a true timesaver that provides us with measurements we can trust.

In patients with glaucoma, there is a possibility of their eye pressure either fluctuating significantly or being outside the target range (as determined by their doctor). Both these changes are associated with worsening of glaucoma. Monitoring for these changes between office visits can help reassure the doctor and the patient that the therapy is adequate and that the patient is compliant with treatment. If the eye pressure is not stable, then the doctor can recommend additional treatment or tailor the eye drop regimen to stabilize the pressure before permanent loss of tissue or visual field occurs.

In patients with suspected glaucoma, daily intraocular pressure monitoring is also essential. In a high proportion of these patients, IOP elevations may be missed during regular scheduled examinations. Knowing these pres- sure peaks exist can help control the disease and person- alize and optimize the treatment regimen. Autotonometry is an efficient option for this purpose, as well as being comfortable for the patient.

Taking normal iCare measurements is very straight-forward – I can train novice technicians in 15 minutes. Teaching patients to take their own measurements takes a little longer but is time well spent (around 20 minutes to set-up the device to fit their face and train). The effort is worthwhile because when the patient returns you have a set of IOP measurements for both eyes taken at different times day.

iCare HOME is a game changer in the way we manage glaucoma.

The ability for patients to measure their own IOP has the potential to transform glaucoma care. By using home monitoring, we can obtain far more IOP measurements to more accurately identify peak IOP and gain greater appreciation of IOP fluctuations. Most patients find iCare HOME easy to use and as IOP measurements can be uploaded to the cloud, the clinician can view results remotely. In my practice, the introduction of iCare HOME has allowed us to move away from office-hour IOP phasing and has provided improved insight into IOP as a risk factor for glaucoma progression.

In our study, the Icare ic200 overestimated the IOP. The overestimation increased as the baseline IOP increased. The agreement between the IOP measurement by GAT and Icare ic200 was <2 mm Hg at all ranges of IOP. The narrow limits of agreement between the tonometers for an IOP <21 mm Hg makes it a useful alternative to GAT in this pressure range.

There was excellent agreement between the IC200 and GAT tonometers, both in healthy subjects and PCG, with a trend to overestimate IOP when measured with IC200. There was no influence by CCT on IOP measurements in patients with PGC.

The use of Icare tonometry decreased the need of EUAs to evaluate children with glaucoma and significantly increased successful IOP measurement in clinic.